Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy

Ranjita Misra ¹ * , Bamadeb Patra ², Sudha Varadharaj ², Rama Shanker Verma ² *

Cited by CrossRef: 7

1- Torres Quintas S, Canha‐Borges A, Oliveira M, Sarmento B, Castro F. Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple‐Negative Breast Cancer Treatment. Small. 2023; [Crossref]

2- Parthiban A, Sachithanandam V, Sarangapany S, Misra R, Muthukrishnan P, Jeyakumar T, Purvaja R, Ramesh R. Green synthesis of gold nanoparticles using quercetin biomolecule from mangrove plant, Ceriops tagal: Assessment of antiproliferative properties, cellular uptake and DFT studies. Journal of Molecular Structure. 2023;1272:134167 [Crossref]

3- Reddy Baddam S, Ganta S, Nalla S, Banoth C, Vudari B, Akkiraju P, Srinivas E, Tade R. Polymeric nanomaterials-based theranostic platforms for triple-negative breast cancer (TNBC) treatment. International Journal of Pharmaceutics. 2024;660:124346 [Crossref]

4- Chaudhuri A, Kumar D, Dehari D, Patil R, Singh S, Kumar D, Agrawal A. Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology. Cancers. 2023;15(9):2661 [Crossref]

5- Wagh H, Bhattacharya S. Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms. Critical Reviews in Oncology/Hematology. 2024;204:104505 [Crossref]

6- Bazzazan M, Fathollazadeh P, Keshavarz Shahbaz S, Rezaei N. Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: Current status and future perspectives. International Journal of Pharmaceutics. 2024;664:124639 [Crossref]

7- Dinakar Y, Rajana N, Kumari N, Jain V, Mehra N. Recent Advances of Multifunctional PLGA Nanocarriers in the Management of Triple-Negative Breast Cancer. AAPS PharmSciTech. 2023;24(8) [Crossref]

8- Cai L, Xu X, Chen W. The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems. Pharmaceutics. 2022;14(8):1647 [Crossref]

9- Vysyaraju N, Paul M, Ch S, Ghosh B, Biswas S. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer. Journal of Drug Targeting. 2022;:1 [Crossref]

10- Anwer M, Ali E, Iqbal M, Ahmed M, Aldawsari M, Saqr A, Alalaiwe A, Soliman G. Development of Chitosan-Coated PLGA-Based Nanoparticles for Improved Oral Olaparib Delivery: In Vitro Characterization, and In Vivo Pharmacokinetic Studies. Processes. 2022;10(7):1329 [Crossref]

11- Misra R, Hazra S, Saleem S, Nehru S. Drug-loaded polymer-coated silver nanoparticles for lung cancer theranostics. Med Oncol. 2024;41(6) [Crossref]

12- Sargazi S, Mukhtar M, Rahdar A, Barani M, Pandey S, Díez-Pascual A. Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review. IJMS. 2021;22(19):10319 [Crossref]

13- Quijia C, Enríquez A, Zappia C, Peroni R, Chorilli M. Administration of Inhibitory Molecules through Nanoparticles in Breast Cancer Therapy. CMC. 2024;31(6):726 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons